蓝帆医疗股份有限公司 第六届董事会第三十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第三十七次会议于2026年1月4日以电子邮件的 方式发出通知，于2026年1月7日以通讯表决的方式召开。本次会议应参加会议董事8人，实际参加会议 董事8人，全体董事以通讯的方式出席会议。公司董事长刘文静女士主持了本次会议。会议的通知、召 开、表决程序符合《中华人民共和国公司法》和《蓝帆医疗股份有限公司章程》的规定。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002382 证券简称：蓝帆医疗 公告编号：2026-003 债券代码：128108 债券简称：蓝帆转债 二、董事会会议审议情况 1、审议并通过了《关于董事会提议向下修正"蓝帆转债"转股价格的议案》； 截至2026年1月7日，公司股票已出现连续三十个交易日中至少有十五个交易日的收盘价低于当期转股价 格85%的情形，已触发"蓝帆转债"转股价格向下修正条件。 为充分保护债券持有人利益，优化公司资本结构，支持公司长期 ...

Core Viewpoint - Boston Scientific (BSX) is showing potential as a stock pick due to its recent technical performance and positive earnings estimate revisions [1][3]. Technical Analysis - BSX has surpassed the 50-day moving average, indicating a short-term bullish trend [1]. - The stock has increased by 5.7% over the past four weeks, suggesting upward momentum [2]. Earnings Estimates - There have been no downward revisions for BSX's earnings estimates in the past two months, with one upward revision noted [3]. - The consensus estimate for BSX has also increased, reinforcing the bullish outlook for the stock [3]. Market Position - BSX is currently rated as a Zacks Rank 2 (Buy), indicating strong potential for continued growth [2].

1月7日，上交所连开两张"罚单"，分别对科创板公司亚辉龙、英集芯及有关责任人予以监管警示，原因为相关公司在披露涉及"脑机接口"业务信息时存 在不准确、不完整的情形。 | 证券代码 | 证券简称 | 监管类型 | 外理事由 | 涉及对象 | 外理日期 | | --- | --- | --- | --- | --- | --- | | 688575 | 亚辉龙 | 监管警示 | 关于深圳市亚辉龙生物科技股份有 | 上市公司,董秘 | 2026-01-07 | | | | | 限公司的决定书 | | | | 688209 | 英集示 | 监管警示 | 关于深圳英集芯科技股份有限公司 | 上市公司,董秘 | 2026-01-07 | | | | | 的地完书 | | | 亚辉龙1月6日股价上涨6.52%、成交量较前一个交易日增长299%。当天收盘后，该公司自愿披露与深圳脑机星链科技有限公司签订《战略合作框架协 议》，称双方将在产品研发、市场推广以及股权投资等方面开展合作，并披露后者为"深耕非侵入式与侵入式双技术路径的领先企业"。该公告披露后引 发市场关注，上交所火速下发问询函，要求公司说明合作具体情况。在监管督促下， ...

1月7日，上交所连开两张"罚单"，分别对科创板公司亚辉龙、英集芯及有关责任人予以监管警示，原因为相关公司在披露涉及"脑 机接口"业务信息时存在不准确、不完整的情形。 | 证券代码 | 证券简称 | 监管类型 | 外理事由 | 涉及对象 | 处理日期 | | --- | --- | --- | --- | --- | --- | | 688575 | 亚辉龙 | 监管警示 | 关于深圳市亚辉龙生物科技股份有 | 上市公司,董秘 | 2026-01-07 | | | | | 限公司的决定书 | | | | 688209 | 英集芯 | 监管警示 | 关于深圳英集芯科技股份有限公司 | 上市公司,董秘 | 2026-01-07 | | | | | 的决定书 | | | 亚辉龙1月6日晚自愿披露与脑机接口相关公司的框架协议，当晚收到上交所问询函，要求其进一步核实情况。另一家科创板公司英集芯也在1月 6日通过投资者互动平台透露关于脑机接口芯片领域的早期投资布局，因内容语焉不详，易引起误导，被上交所下发监管工作函。当前，两家公 司均已补充披露公告说明业务风险。 近期，"脑机接口"成为市场热点，多家公司股价连续涨停，引发监 ...

Group 1 - Fenglong Co., Ltd. has experienced a significant stock price increase, with a cumulative rise of over 100% in just eight trading days, leading to potential trading suspension if the abnormal price trend continues [2] - ST Sunshine is undergoing a control change process by its major shareholder, which may lead to a change in the actual controller, resulting in a stock suspension for up to two trading days [3] - Yihuilong's collaboration with Brain Machine Star Chain has not yet received medical device registration, with potential revenue generation not expected before November 2026 [4] Group 2 - Zhuhai Ming Technology's subsidiary has acquired 66,900 shares of Zhipu in Hong Kong, amounting to approximately 7.77 million HKD [5] - Beifang Navigation clarified that it has no business or orders related to commercial aerospace, despite being included in that sector by some online platforms [6] - ST Energy is required to pay a total of 7.59 million CNY to investors due to a court ruling on false statements, with a joint liability for 8% of the compensation by Daxin [7] Group 3 - Heng Rui Medicine's innovative drug, Rilaforpu α injection, has been approved for market release, with no similar products available domestically or internationally [8] - Bibet has not yet achieved profitability and has accumulated losses, with ongoing significant R&D investments required [9] - Chengjian Development reported that its investment in Century Space is currently unprofitable, with no undisclosed earnings expected [10] Group 4 - Guo New Energy anticipates a net loss for 2025 due to industry cycle fluctuations and market changes [12] - Kouzi Jiao expects a 50%-60% decrease in net profit for 2025, primarily due to declining sales of high-end products [13] - CIMC Group's sale of properties is expected to reduce its net profit by approximately 1.08 billion CNY, significantly impacting its 2025 earnings [14] Group 5 - Chuanjinno expects a net profit increase of 144%-173% for 2025, driven by strong market demand and improved production efficiency [15][16] - Zhongke Lanyun forecasts a net profit increase of 366.51%-376.51% for 2025, attributed to significant gains from investments [17] - China Shipbuilding Technology anticipates a net loss for 2025, as per preliminary financial assessments [18] Group 6 - Yijing Optoelectronics expects a net loss for 2025, with projections indicating a potential negative net asset position by year-end [19] - Tuo Jing Technology's major shareholder plans to reduce its stake by up to 1.30% due to funding needs [21] - Yili Group's chairman plans to sell up to 0.98% of shares to repay financing obligations [22] Group 7 - Guangqi Technology's subsidiary has signed contracts totaling 264 million CNY for the production of metamaterials [28] - Metro Design's subsidiary has secured a 311 million CNY contract for comprehensive energy management services with a hospital [29]

智通财经APP讯，精锋医疗-B(02675)公布配发结果，公司全球发售2772.22万股H股，超额分配发售 415.83万股。香港公开发售项下最终发售股份数目占全球发售的(超额分配后)8.70%，国际发售项下最终 发售股份数目占全球发售的(超额分配后)91.30%。每股发售价43.24港元，全球发售净筹约11.17亿港 元。每手100股，预期股份将于2026年1月8日上午九时正在联交所开始买卖。 其中，香港公开发售获1091.94倍认购，国际发售获25.18倍认购。 ...

北京商报讯（记者 丁宁）在收到上交所问询函后，1月7日晚间，亚辉龙（688575）对问询函内容进行 了回复。 亚辉龙还表示，脑机星链成立时间短，规模较小，推进后续研发需要扩大融资规模，公司短期内不排除 有股权投资、合资等合作安排，但预计投资金额较小，对公司不会有重大影响。 据了解，近期，亚辉龙与深圳脑机星链科技有限公司（以下简称"脑机星链"）签署《战略合作框架协 议》。公告披露，脑机星链成立于2025年9月，注册资本为500万元，主营业务包括脑疾病综合诊断、治 疗与康复。根据框架协议，双方将合作开展市场推广并进行销售收入分成。亚辉龙在问询函回复中表 示，脑机星链在严肃医疗场景下与亚辉龙拟合作的相关产品尚未取得医疗器械注册证，预计最早拿证产 品为迷走神经刺激仪（暂定名，以最终获批为准），能否获证存在不确定性，如果获批，预计公司最早 产生收益的时间不早于2026年11月，且产品上市后的具体销售情况还取决于市场环境等情况，公司相关 市场销售渠道资源转化存在不确定性，本次合作对公司业务无重大影响。 ...

其中，香港公开发售获1091.94倍认购，国际发售获25.18倍认购。 精锋医疗-B(02675)公布配发结果，公司全球发售2772.22万股H股，超额分配发售415.83万股。香港公开 发售项下最终发售股份数目占全球发售的(超额分配后)8.70%，国际发售项下最终发售股份数目占全球 发售的(超额分配后)91.30%。每股发售价43.24港元，全球发售净筹约11.17亿港元。每手100股，预期股 份将于2026年1月8日上午九时正在联交所开始买卖。 ...

Core Viewpoint - Jindalai (688057) is making strategic investments in JiCi Medical and Zhongke Hongtai to enhance its presence in the fields of autologous cell technology and vascular interventional surgical robots, respectively [1] Group 1: Stock Performance - As of January 7, 2026, Jindalai's stock closed at 12.45 yuan, down 0.16% from the previous trading day, with a total market capitalization of 3.436 billion yuan [1] - The stock opened at 12.54 yuan, reached a high of 12.58 yuan, and a low of 12.42 yuan, with a trading volume of 15.0675 million yuan and a turnover rate of 0.44% [1] Group 2: Investment Announcements - Jindalai plans to invest 280 million yuan in JiCi Medical, acquiring a 34.00% stake; JiCi Medical focuses on the research and development of autologous cell technology and holds multiple invention patents, led by Professor Hu Min [1] - The investment in Zhongke Hongtai aims to establish a foothold in the vascular interventional surgical robot sector, with related products currently undergoing special review procedures for national innovative medical devices [1] - The announcement also details the purpose of the investments, valuation basis, synergistic effects, and risk management measures [1]

每经AI快讯，1月7日，亚辉龙(688575.SH)回复上交所问询函，公司与脑机星链合作的相关产品尚未取 得医疗器械注册证，预计最早产生收益时间不早于2026年11月。公司与脑机星链拟合作研发的相关领域 均为非侵入式技术路径，目前尚处于在早期阶段，相关项目预估研发投入3000万元左右。脑机星链成立 时间短，规模较小，推进后续研发需要扩大融资规模，公司短期内不排除有股权投资、合资等合作安 排，但预计投资金额较小，对公司不会有重大影响。 ...